Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efectos del Complejo 2-Aticyto y la D-Ribosa sobre el Dolor y la Evolución Clínica en Pacientes con Fibromialgia

16 de septiembre de 2026 actualizado por: Kubra Neslihan Kurt Oktay, Haydarpasa Numune Training and Research Hospital

Efectos del Complejo 2-Aticyto y la D-Ribosa sobre el Dolor, los Síntomas y la Evolución Clínica en Pacientes con Síndrome de Fibromialgia

This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.

Descripción general del estudio

Descripción detallada

Fibromyalgia syndrome is a chronic condition associated with widespread pain, fatigue, sleep disturbance, and reduced quality of life. Although standard pharmacologic treatments such as pregabalin and duloxetine are commonly used, symptom control may remain incomplete in many patients. This study was designed to investigate whether adding a supplement containing 2-Aticyto Complex and D-ribose to ongoing standard treatment can improve clinical outcomes in adults with fibromyalgia syndrome.

This is a multicenter, randomized, double-blind, placebo-controlled clinical study. Adults aged 18 to 65 years with fibromyalgia syndrome, diagnosed according to the ACR 2016 criteria, followed for at least 1 year, and receiving pregabalin and/or duloxetine treatment for at least 3 months will be eligible for participation. Major exclusion criteria include rheumatologic disease, renal failure, hepatic failure, cardiovascular disease, diabetes or hypoglycemia, neurologic disease, use of other supplements, allergy to study product ingredients, inability to complete study procedures, or refusal to participate.

After eligibility assessment and informed consent, participants will be randomly assigned to one of two study groups: placebo plus ongoing standard treatment or FibroThol plus ongoing standard treatment. The study treatment will be administered orally at a dose of 15 mL three times daily for 4 weeks. Study visits and assessments will be performed at baseline, week 2, and week 4.

Outcome measures will include pain intensity, neuropathic pain, fibromyalgia-related functional status, fatigue, sleep quality, anxiety, and depression, assessed using validated clinical scales. Safety will be evaluated through adverse event monitoring during the study period.

A total of 200 participants will be enrolled, with 100 participants assigned to the FibroThol group and 100 participants assigned to the placebo group. The primary objective is to determine whether the addition of 2-Aticyto Complex and D-ribose to standard treatment provides additional benefit in reducing pain and improving symptoms and overall clinical course in patients with fibromyalgia syndrome.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Kubra Neslihan Kurt Oktay, MD
  • Número de teléfono: +905352916609
  • Correo electrónico: drneslihankurt@gmail.com

Ubicaciones de estudio

      • Istanbul, Turquía (Türkiye), 34480
        • University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation
        • Contacto:
      • Istanbul, Turquía (Türkiye), 34668
        • University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • Contacto:
        • Sub-Investigador:
          • Emre Ata, MD
      • Istanbul, Turquía (Türkiye), 34732
        • Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation
        • Contacto:
      • Istanbul, Turquía (Türkiye), 34752
        • University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • Contacto:
          • Ozge Gulsum Illeez, MD
          • Número de teléfono: +905326255684
          • Correo electrónico: ozgeilleez@gmail.com
    • Istanbul
      • Istanbul, Istanbul, Turquía (Türkiye), 34662
        • University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • Contacto:
        • Sub-Investigador:
          • Arzu Erbilici, MD
        • Sub-Investigador:
          • Duygu Geler Kulcu, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 18 to 65 years
  • Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
  • Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
  • Receiving pregabalin and/or duloxetine treatment for at least 3 months
  • Able to live independently in the community
  • Literate and able to record symptoms and responses
  • No cognitive dysfunction that would interfere with answering study questions
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Rheumatologic disease
  • Renal failure
  • Hepatic failure
  • Cardiovascular disease
  • Hypoglycemia or diabetes mellitus
  • Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
  • Known allergy or hypersensitivity to any active or excipient component of the study syrup
  • Use of any other dietary supplement or nutritional support product during the study period
  • Pregnancy or lactation
  • Active malignancy
  • Active infection
  • Severe psychiatric disease that may interfere with study participation or assessment
  • Refusal to participate or inability to provide informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo Plus Standard Treatment

Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine.

A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor.

Experimental: FibroThol Plus Standard Treatment

Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine.

An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
Periodo de tiempo: Baseline, Week 2, and Week 4

Pain intensity will be assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Neuropathic Pain Measured by DN4
Periodo de tiempo: Baseline, Week 2, and Week 4

Neuropathic pain symptoms will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire, with a total score range of 0 to 10. Higher scores indicate more neuropathic pain features, and a score of 4 or more suggests neuropathic pain. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Fibromyalgia Impact Questionnaire Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement.

Baseline, Week 2, and Week 4
Change in Fibromyalgia Participation Questionnaire Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Fatigue severity will be assessed using the Fatigue Severity Scale, a 9-item scale with a total score range of 9 to 63. Higher scores indicate greater fatigue severity. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Fatigue Severity Scale (FSS) Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement.

Baseline, Week 2, and Week 4
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, with a global score range of 0 to 21. Higher scores indicate poorer sleep quality. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Beck Depression Inventory Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Depressive symptoms will be assessed using the Beck Depression Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe depressive symptoms. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Beck Anxiety Inventory Score
Periodo de tiempo: Baseline, Week 2, and Week 4

Anxiety symptoms will be assessed using the Beck Anxiety Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe anxiety symptoms. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Kubra Neslihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
  • Silla de estudio: Kubra Nesihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

4 de octubre de 2026

Finalización primaria (Estimado)

4 de mayo de 2027

Finalización del estudio (Estimado)

4 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

23 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de marzo de 2026

Publicado por primera vez (Actual)

27 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared. Aggregate results will be reported in publications and trial registry updates.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir